Compare RFL & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RFL | MSD |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Trusts Except Educational Religious and Charitable |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.1M | 136.4M |
| IPO Year | 2017 | N/A |
| Metric | RFL | MSD |
|---|---|---|
| Price | $1.05 | $6.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 53.3K | ★ 84.7K |
| Earning Date | 12-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.26% |
| EPS Growth | ★ 44.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $0.99 | $6.61 |
| 52 Week High | $3.96 | $7.94 |
| Indicator | RFL | MSD |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 45.24 |
| Support Level | $0.99 | $6.61 |
| Resistance Level | $1.38 | $7.44 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 12.88 | 38.99 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.